Table 2.
Neuropsychological data for patients with amyloid-negative (Aβneg aMCI) and amyloid-positive (Aβpos aMCI) amnestic mild cognitive impairment
| Measure | Aβneg aMCI, mean ± SD | Aβpos aMCI, mean ± SD | Group comparison |
|---|---|---|---|
| Free recall (episodic memory) | −2.0 ± 1.3 | −3.0 ± 1.5 | Pt-test = .02; Aβneg aMCI > Aβpos aMCI |
| Recognition (episodic memory) | −3.5 ± 3.2 | −8.2 ± 5.1 | Pt-test< .001; Aβneg aMCI > Aβpos aMCI |
| Verbal fluency | −1.1 ± 1.5 | −0.9 ± 1.7 | Pt-test = .67 |
| Languagea | 6/13 | 18/6 | Pχ2< .005; Aβpos aMCI > Aβneg aMCI |
| Short-term memory | −0.02 ± 1.1 | −0.1 ± 1.3 | Pt-test = .90 |
| Working memory | −0.7 ± 0.7 | −0.1 ± 0.9 | Pt-test = .01; Aβpos aMCI > Aβneg aMCI |
| Executive functions | −1.0 ± 3.1 | −0.2 ± 1.9 | Pt-test = .31 |
| Visuospatial functions | −1.4 ± 1.8 | −2.0 ± 4.8 | Pt-test = .64 |
NOTE. Scores and composite scores are expressed as W-scores relative to Aβneg HC (by definition, Aβneg HC mean ± SD = 0.0 ± 1.0).
Between-group differences were assessed using t-tests and for categorical variable, χ2 test. P values < .00625 (significant P values after Bonferroni correction for multiple comparisons) are in bold.
a
Indicated is number of no error cases/number of one error or more cases.